Varlitinib

Drug Profile

Varlitinib

Alternative Names: ARRY-334543; ARRY-543; ASLAN-001; Varlitinib tosylate

Latest Information Update: 20 Dec 2016

Price : $50

At a glance

  • Originator Array BioPharma
  • Developer Array BioPharma; ASLAN Pharmaceuticals
  • Class Antineoplastics; Quinazolines; Small molecules
  • Mechanism of Action Epidermal growth factor receptor antagonists; ERBB 2 receptor antagonists; ERBB 4 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Cholangiocarcinoma; Gastric cancer
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Breast cancer; Cholangiocarcinoma; Gastric cancer
  • Phase I/II Biliary cancer
  • Phase I Solid tumours

Most Recent Events

  • 01 Nov 2016 Phase-I/II clinical trials in Biliary cancer (First-line therapy, Combination therapy, Late-stage disease, Inoperable/Unresectable, Metastatic disease) in Taiwan, Singapore (PO) (NCT02992340)
  • 18 Jul 2016 Biomarkers information updated
  • 24 Jun 2016 Varlitinib receives Orphan Drug status for Gastric cancer in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top